Dan discusses the copay smoothing provision of the IRA and the potential impact on Medicare drug plans. In addition, he proposes several ways that pharmaceutical companies can educate consumers and providers on copay smoothing to improve drug uptake and adherence.
NCQA’s Healthcare Effectiveness Data and Information Set (HEDIS), beginning with the Measurement Year 2022 and ramping up through MY2024, will begin stratifying selected performance measures by race and ethnicity. The idea is that through HEDIS reporting, health plans will be able to identify and address inequities in healthcare and be held accountable for taking these actions.
Dive into the use of data analytics and real-world evidence in supporting therapy choices for patients with Dan Danielson as he highlights some of the emerging tools being used.
Health economics and outcomes research (HEOR) and health technology assessment (HTA) value frameworks have been gaining leverage. Dan Danielson walks us through how their impact is expanding, including their scope and evolving influence in healthcare and access.
New healthcare policies undoubtedly mean a shift in market access. In this article, Precision’s Dan Danielson explores the high-level potential market consequences in 2 major segments of the US healthcare environment and the rationale behind each: the healthcare systems and hospitals that deliver care, and pharmaceutical manufacturers who develop new drug therapies for the patients served by the health systems.
With the COVID pandemic still firmly gripping the US, developing and implementing plans to address the crisis on “day one” is a top priority agenda item. But what else makes the list? Dan Danielson reviews the top 2 agenda items for the Biden Administration and the impact on regional health plans.
The current healthcare market is dominated by partnerships, mergers, and healthcare giants. Dan Danielson explores 2 examples of how smaller, regional health plans can stay in the mix and competitive with the big kids on the block.
Dan Danielson examines the impact of 2019 policy proposals changes on regional health plans, and notes that uncertainty from stakeholders has created the need for manufacturers to provide concise messaging that emphasizes value to payers.
Dan Danielson examines the incentives for regional plans offering exclusion formularies, and how the next iteration of exclusions is designed to keep plans competitive and relevant in an environment rich with acquisitions and mergers.
Access Experience Team member Dan Danielson documents the launch of Premera’s Value-Based Formulary (VBRx), and the development of its nontraditional tiers for defining and demonstrating value.
